• Dutasteride: Designing Mechanism-First Assays

  2026-08-18

  Dutasteride is a dual 5-alpha-reductase inhibitor suited to layered studies of DHT biology, prostate cancer research, and apoptosis. This article shows how an immunometabolic liver-injury study can sharpen assay design without overstating cross-domain evidence.

• ACE2, Diminazene Aceturate, and Septic Cardiomyopathy

  2026-08-18

  The reference study identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and shows that pharmacological ACE2 activation with diminazene aceturate protects septic mice. Its central contribution is the proposed MasR-Sirt1 pathway, which connects ACE2 signaling with mitochondrial biogenesis, cardiac function, inflammation, oxidative stress, and apoptosis.

• HIF-1–tiR-Lys Protects Renal Cells From Ferroptosis

  2026-08-17

  Li and colleagues identify tiRNA-Lys-CTT-003 as a downstream effector of HIF-1α that protects renal tubular cells from cisplatin-associated ferroptosis. Their evidence connects tiR-Lys to the RNA-binding protein GRSF1 and GPX4, providing a post-transcriptional explanation for how HIF activation limits oxidative tubular injury in acute kidney injury.

• Phosphatase Inhibitor Cocktail 2 Workflow Guide

  2026-08-17

  Protect phosphorylation-dependent signaling readouts in liver, cell, and tissue lysates with a practical 100X workflow. This guide connects phosphoprotein preservation to the CerS6–C16:0 ceramide stress model and shows how to optimize Western blotting, immunoprecipitation, mitochondrial studies, and related assays.

• Tin Mesoporphyrin IX: Translational HO Control

  2026-08-16

  A mechanistic and strategic guide to using Tin Mesoporphyrin IX (chloride) as a research tool for heme oxygenase inhibition, metabolic disease research, insulin resistance study design, and hypothesis-driven antiviral investigation.

• Chloramphenicol for Plasmid Selection Workflows

  2026-08-15

  Chloramphenicol enables controlled plasmid selection, marker maintenance, and resistance-plasmid tracking without confusing selectable genotype with clinical phenotype. This workflow-focused guide connects a bacterial protein synthesis inhibitor with recent evidence on plasmid-borne carbapenemase transmission and shows how to improve assay reliability.

• Talabostat Mesylate: Enzyme-to-Phenotype Assays

  2026-08-15

  Talabostat mesylate (PT-100) enables mechanistic studies of DPP4 and FAP inhibition from substrate cleavage to immune and tissue phenotypes. This article presents a phenotype-first assay strategy and explains how recent epidermal homeostasis research can sharpen experimental interpretation without implying an unproven NLRP10 interaction.

• Ziprasidone HCl: Permeability and Cancer Workflows

  2026-08-14

  Build reproducible Caco-2 permeability, cancer-cell, and receptor-pathway experiments around Ziprasidone HCl. This guide connects formulation-aware handling with GOT1-focused oncology assays while distinguishing evidence from practical optimization.

• Ajugol, Mitophagy, and Pyroptosis in Gout

  2026-08-14

  The reference study identifies PI3K/AKT/mTOR suppression as the mechanistic link between ajugol treatment, restored PINK1/Parkin-dependent mitophagy, and reduced chondrocyte pyroptosis in acute gouty arthritis. Its combined computational, cellular, and animal strategy supports mitochondrial quality control as a potential way to limit MSU-driven cartilage inflammation, while also highlighting the need for careful pathway-specific validation.

• Pentoxifylline and Preterm Monocyte Hyperinflammation

  2026-08-13

  Schüller et al. developed an age-comparative in vitro model showing that pentoxifylline suppresses LPS-driven monocyte activation in preterm and term infants as well as adults. The study links reduced inflammatory cytokine production to lower cellular and transcriptional TLR4 activity, while also identifying age-dependent effects on surface markers, IL-10 production, and phagocytosis.

• 25-Hydroxycholesterol Reprograms Immunosuppressive TAMs

  2026-08-13

  Xiao et al. identify CH25H and lysosomal 25-hydroxycholesterol as an immunometabolic checkpoint that reinforces tumor-associated macrophage suppression through a GPR155–mTORC1–AMPKα–STAT6 pathway. The study links cholesterol handling to macrophage metabolic state, T-cell surveillance, and anti-PD-1 response, providing a mechanistic framework for studying cold-to-hot tumor conversion.

• Epinephrine Bitartrate for Adrenergic Assays

  2026-08-12

  Epinephrine Bitartrate offers a practical way to stimulate α- and β-adrenergic responses across cardiovascular, airway, immune, and neurobiology models. This guide combines concentration planning, fresh-solution handling, time-resolved assay design, and reference-informed troubleshooting for more reproducible experiments.

• NVP-BGJ398 phosphate: FGFR Research Workflows

  2026-08-12

  NVP-BGJ398 phosphate enables pathway-focused studies across FGFR1–3-driven cancer models and FGFR3-dependent skeletal disease systems. This practical guide covers formulation, phospho-signaling assays, phenotype validation, and troubleshooting for reproducible preclinical experiments.

• Prochlorperazine: D2 Antagonist in Research

  2026-08-11

  Prochlorperazine is a phenothiazine dopamine D2 receptor antagonist used in antiemetic therapy and investigated in melanoma research. Supplier-reported data support defined in vitro concentration windows, melanoma-cell EC50 benchmarks, and mechanistic hypotheses that require validation outside cell culture.

• Netarsudil (AR-13324) for Reliable Cell Assays

  2026-08-10

  This scenario-based guide explains how Netarsudil (AR-13324), SKU B7807, can help researchers distinguish ROCK-driven cytoskeletal effects from genuine viability or cytotoxicity changes. It covers assay design, formulation, controls, data interpretation, siRNA codelivery evidence, and practical product-selection criteria.

444 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page